Skip to main content
. Author manuscript; available in PMC: 2024 Feb 19.
Published in final edited form as: Nat Med. 2023 Sep 7;29(10):2481–2488. doi: 10.1038/s41591-023-02543-w

Extended Data Fig. 1 |. Baseline and Post-Treatment ADRD Plasma and Cerebrospinal Fluid Biomarkers Assessed Using the Simoa® Quanterix HD-X Analyzer.

Extended Data Fig. 1 |

Baseline and post-treatment values for each analyte color-coded by participant as listed in Table 2. Mean [95% CI]: CSF (a) pTau-181, −12.04 [−34.01 to 9.930]; (b) pTau-231, −1.304 [−25.19 to 22.58]; (c) NfL,−23.20 [−695.6 to 649.2]; (d) GFAP, 2560 [440.9 to 4679]; (e) Aß40, 148.9 [−1359 to 1656]; (f) Aß42, −3.110 [−96.96 to 90.74]. Plasma, mean [95% CI]: (g) pTau-181, −0.0042 [−0.8779 to 0.8695]; (h) NfL, −1.774 [−9.567 to 6.019]; (i) GFAP, 24.29 [−42.74 to 91.32]; ( j) Aß40, −0.6714 [−13.04 to 11.69]; (k) Aß42, −0.1080 [−0.6495 to 0.4335]. Baseline to post-treatment values were assessed using two-sided paired sample t-tests, p < 0.05. 95% CI: 95 percent confidence interval for the post vs baseline mean difference. No correction for multiple comparisons was made due to small sample size (N = 5). CSF: Cerebrospinal fluid.